Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 349 to 350 of 350 entries
Sorted by: Best Match Show Resources per page
Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial.

JAMA cardiology

Mayer K, Hein-Rothweiler R, Schüpke S, Janisch M, Bernlochner I, Ndrepepa G, Sibbing D, Gori T, Borst O, Holdenrieder S, Kupka D, Petzold T, Bradaric C, Okrojek R, Leistner DM, Trippel TD, Münzel T, Landmesser U, Pieske B, Zeiher AM, Gawaz MP, Hapfelmeier A, Laugwitz KL, Schunkert H, Kastrati A, Massberg S.
PMID: 33787834
JAMA Cardiol. 2021 Jul 01;6(7):753-761. doi: 10.1001/jamacardio.2021.0475.

IMPORTANCE: The assessment of new antithrombotic agents with a favorable safety profile is clinically relevant.OBJECTIVE: To test the efficacy and safety of revacept, a novel, lesion-directed antithrombotic drug, acting as a competitive antagonist to platelet glycoprotein VI.DESIGN, SETTING, AND...

Cite
Mayer K, Hein-Rothweiler R, Schüpke S, et al. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. JAMA Cardiol. 2021;6(7):753-761doi: 10.1001/jamacardio.2021.0475.
Mayer, K., Hein-Rothweiler, R., Schüpke, S., Janisch, M., Bernlochner, I., Ndrepepa, G., Sibbing, D., Gori, T., Borst, O., Holdenrieder, S., Kupka, D., Petzold, T., Bradaric, C., Okrojek, R., Leistner, D. M., Trippel, T. D., Münzel, T., Landmesser, U., Pieske, B., Zeiher, A. M., Gawaz, M. P., Hapfelmeier, A., Laugwitz, K. L., Schunkert, H., Kastrati, A., & Massberg, S. (2021). Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. JAMA cardiology, 6(7), 753-761. https://doi.org/10.1001/jamacardio.2021.0475
Mayer, Katharina, et al. "Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial." JAMA cardiology vol. 6,7 (2021): 753-761. doi: https://doi.org/10.1001/jamacardio.2021.0475
Mayer K, Hein-Rothweiler R, Schüpke S, Janisch M, Bernlochner I, Ndrepepa G, Sibbing D, Gori T, Borst O, Holdenrieder S, Kupka D, Petzold T, Bradaric C, Okrojek R, Leistner DM, Trippel TD, Münzel T, Landmesser U, Pieske B, Zeiher AM, Gawaz MP, Hapfelmeier A, Laugwitz KL, Schunkert H, Kastrati A, Massberg S. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. JAMA Cardiol. 2021 Jul 01;6(7):753-761. doi: 10.1001/jamacardio.2021.0475. PMID: 33787834; PMCID: PMC8014195.
Copy Download .nbib Format: NLM
Global health burden of ambient PM.

Environment international

Chowdhury S, Pozzer A, Haines A, Klingmüller K, Münzel T, Paasonen P, Sharma A, Venkataraman C, Lelieveld J.
PMID: 34894485
Environ Int. 2021 Dec 08;159:107020. doi: 10.1016/j.envint.2021.107020. Epub 2021 Dec 08.

Chronic exposure to fine particulate matter (PM

Cite
Chowdhury S, Pozzer A, Haines A, et al. Global health burden of ambient PM. Environ Int. 2021;159:107020doi: 10.1016/j.envint.2021.107020.
Chowdhury, S., Pozzer, A., Haines, A., Klingmüller, K., Münzel, T., Paasonen, P., Sharma, A., Venkataraman, C., & Lelieveld, J. (2021). Global health burden of ambient PM. Environment international, 159107020. https://doi.org/10.1016/j.envint.2021.107020
Chowdhury, Sourangsu, et al. "Global health burden of ambient PM." Environment international vol. 159 (2021): 107020. doi: https://doi.org/10.1016/j.envint.2021.107020
Chowdhury S, Pozzer A, Haines A, Klingmüller K, Münzel T, Paasonen P, Sharma A, Venkataraman C, Lelieveld J. Global health burden of ambient PM. Environ Int. 2021 Dec 08;159:107020. doi: 10.1016/j.envint.2021.107020. Epub 2021 Dec 08. PMID: 34894485.
Copy Download .nbib Format: NLM
Showing 349 to 350 of 350 entries